Meena Balasubramanian

Prof. Meena Balasubramanian

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
VFVíctor Faundes
Víctor Faundes
WNWilliam Newman
William Newman
LBLaura Bernardini
Laura Bernardini
NCNatalie Canham
Natalie Canham
JCJill Clayton-Smith
Jill Clayton-Smith
MHMatthew E. . Hurles
Matthew E. . Hurles

29 April 2014 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
KKKim M. Keppler‐Noreuil
Kim M. Keppler‐Noreuil
JSJulie C. Sapp
Julie C. Sapp
MLMarjorie J. Lindhurst
Marjorie J. Lindhurst
VPVictoria E.R. Parker
Victoria E.R. Parker
CBCathy Blumhorst
Cathy Blumhorst
LBLeslie G. Biesecker
Leslie G. Biesecker
Somatic mutations in the phosphatidylinositol/AKT/mTOR pathway cause segmental overgrowth disorders. Diagnostic descriptors associated with PIK3CA mutations include fibroadipose overgrowth (FAO), Hemihyperplasia multiple Lipomatosis (HHML), Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/skeletal and spinal (CLOVES) syndrome, macrodactyly, and the megalencephaly syndrome, Megalencephaly‐Capillary malformation (MCAP) syndrome. We set out to refine the understanding of the clinical spectrum and natural history of these phenotypes, and now describe 35 patients with segmental overgrowth and somatic PIK3CA mutations. The phenotypic data show that these previously described disease entities have considerable overlap, and represent a spectrum. While this spectrum overlaps with Proteus syndrome (sporadic, mosaic, and progressive) it can be distinguished by the absence of cerebriform connective tissue nevi and a distinct natural history. Vascular malformations were found in 15/35 (43%) and epidermal nevi in 4/35 (11%) patients, lower than in Proteus syndrome. Unlike Proteus syndrome, 31/35 (89%) patients with PIK3CA mutations had congenital overgrowth, and in 35/35 patients this was asymmetric and disproportionate. Overgrowth was mild with little postnatal progression in most, while in others it was severe and progressive requiring multiple surgeries. Novel findings include: adipose dysregulation present in all patients, unilateral overgrowth that is predominantly left‐sided, overgrowth that affects the lower extremities more than the upper extremities and progresses in a distal to proximal pattern, and in the most severely affected patients is associated with marked paucity of adipose tissue in unaffected areas. While the current data are consistent with some genotype–phenotype correlation, this cannot yet be confirmed. © The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals, Inc.

1 January 2018 in The American Journal of Human Genetics
Verified
Journal Article
Open access
MKMagdalena Koczkowska
Magdalena Koczkowska
YCYunjia Chen
Yunjia Chen
TCTom Callens
Tom Callens
AGAlicia Gomes
Alicia Gomes
ASAngela Sharp
Angela Sharp
LMLudwine M. Messiaen
Ludwine M. Messiaen
Neurofibromatosis type 1 (NF1), a common genetic disorder with a birth incidence of 1:2,000-3,000, is characterized by a highly variable clinical presentation. To date, only two clinically relevant intragenic genotype-phenotype correlations have been reported for NF1 missense mutations affecting p.Arg1809 and a single amino acid deletion p.Met922del. Both variants predispose to a distinct mild NF1 phenotype with neither externally visible cutaneous/plexiform neurofibromas nor other tumors. Here, we report 162 individuals (129 unrelated probands and 33 affected relatives) heterozygous for a constitutional missense mutation affecting one of five neighboring NF1 codons-Leu844, Cys845, Ala846, Leu847, and Gly848-located in the cysteine-serine-rich domain (CSRD). Collectively, these recurrent missense mutations affect ∼0.8% of unrelated NF1 mutation-positive probands in the University of Alabama at Birmingham (UAB) cohort. Major superficial plexiform neurofibromas and symptomatic spinal neurofibromas were more prevalent in these individuals compared with classic NF1-affected cohorts (both p < 0.0001). Nearly half of the individuals had symptomatic or asymptomatic optic pathway gliomas and/or skeletal abnormalities. Additionally, variants in this region seem to confer a high predisposition to develop malignancies compared with the general NF1-affected population (p = 0.0061). Our results demonstrate that these NF1 missense mutations, although located outside the GAP-related domain, may be an important risk factor for a severe presentation. A genotype-phenotype correlation at the NF1 region 844-848 exists and will be valuable in the management and genetic counseling of a significant number of individuals.

7 December 2018 in Science
Verified
Journal Article
Closed access
PDF file
HMHilary C. Martin
Hilary C. Martin
WJWendy D. Jones
Wendy D. Jones
RMRebecca McIntyre
Rebecca McIntyre
GSGabriela Sanchez-Andrade
Gabriela Sanchez-Andrade
MSMark Sanderson
Mark Sanderson
OSon behalf of the Deciphering Developmental Disorders Study
on behalf of the Deciphering Developmental Disorders Study
Genetic architecture of developmental disorders: The genetics of developmental disorders (DDs) is complex. Martin et al. wanted to determine the degree of recessive inheritance of DDs in protein-coding genes. They examined the exomes of more than 6000 families in populations with high and low proportions of consanguineous marriages. They found that 3.6% of DDs in individuals of European ancestry involved recessive coding disorders, less than a tenth of the levels previously estimated. Furthermore, among South Asians with high parental relatedness, rather than most of the disorders arising from inherited variants, fewer than half had a recessive coding diagnosis. Science , this issue p. 1161

5 October 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TSthe DDD study
the DDD study
NANadia Akawi
Nadia Akawi
JMJeremy McRae
Jeremy McRae
MAMorad Ansari
Morad Ansari
Meena BalasubramanianMeena Balasubramanian
Meena Balasubramanian
MHMatthew E Hurles
Matthew E Hurles

16 May 2022 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
ESErika Souche
Erika Souche
SBSergi Beltran
Sergi Beltran
Erwin BrosensErwin Brosens
Erwin Brosens
JBJohn W. Belmont
John W. Belmont
MFMagdalena Fossum
Magdalena Fossum
MWMarjan M. Weiss
Marjan M. Weiss
In 2016, guidelines for diagnostic Next Generation Sequencing (NGS) have been published by EuroGentest in order to assist laboratories in the implementation and accreditation of NGS in a diagnostic setting. These guidelines mainly focused on Whole Exome Sequencing (WES) and targeted (gene panels) sequencing detecting small germline variants (Single Nucleotide Variants (SNVs) and insertions/deletions (indels)). Since then, Whole Genome Sequencing (WGS) has been increasingly introduced in the diagnosis of rare diseases as WGS allows the simultaneous detection of SNVs, Structural Variants (SVs) and other types of variants such as repeat expansions. The use of WGS in diagnostics warrants the re-evaluation and update of previously published guidelines. This work was jointly initiated by EuroGentest and the Horizon2020 project Solve-RD. Statements from the 2016 guidelines have been reviewed in the context of WGS and updated where necessary. The aim of these recommendations is primarily to list the points to consider for clinical (laboratory) geneticists, bioinformaticians, and (non-)geneticists, to provide technical advice, aid clinical decision-making and the reporting of the results.